HBPC.F Stock Overview
Helix BioPharma Corp. operates as an immune-oncology company in Canada.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Helix BioPharma Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.14 |
52 Week High | CA$0.15 |
52 Week Low | CA$0.14 |
Beta | -0.71 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -79.74% |
5 Year Change | -40.13% |
Change since IPO | -94.86% |
Recent News & Updates
Recent updates
Shareholder Returns
HBPC.F | US Biotechs | US Market | |
---|---|---|---|
7D | -7.0% | 0.9% | 0.4% |
1Y | n/a | 10.3% | 28.8% |
Return vs Industry: Insufficient data to determine how HBPC.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how HBPC.F performed against the US Market.
Price Volatility
HBPC.F volatility | |
---|---|
HBPC.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HBPC.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HBPC.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 9 | Jacek Antas | https://www.helixbiopharma.com |
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Helix BioPharma Corp. Fundamentals Summary
HBPC.F fundamental statistics | |
---|---|
Market cap | US$28.82m |
Earnings (TTM) | -US$4.39m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.6x
P/E RatioIs HBPC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HBPC.F income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$5.94m |
Earnings | -CA$5.94m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.027 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did HBPC.F perform over the long term?
See historical performance and comparison